WAVE Life Sciences Ltd.
WVE
$13.02
-$0.33-2.47%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 1.25% | -6.70% | -7.66% | -260.25% | 147.35% |
| Total Depreciation and Amortization | 1.43% | 1.55% | 1.48% | 0.37% | -0.09% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.60% | 4.45% | 25.10% | 52.68% | -8.13% |
| Change in Net Operating Assets | 1,922.52% | 112.30% | 83.10% | 70.27% | -914.53% |
| Cash from Operations | 24.38% | 2.93% | 27.01% | -44.43% | 6.09% |
| Capital Expenditure | 100.40% | 18.95% | -85.45% | -91.86% | 77.55% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.40% | 18.95% | -85.45% | -91.86% | 77.55% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,101.39% | 179.59% | 181.42% | -88.13% | -81.54% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -100.17% |
| Cash from Financing | 1,244.96% | 179.59% | 181.42% | -88.12% | -82.83% |
| Foreign Exchange rate Adjustments | -106.90% | -167.44% | -25.86% | 156.31% | -185.83% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3,412.87% | 64.57% | 41.38% | -566.11% | -105.64% |